18+ · Research use only
PT-141 10mg, Philippines
Peptide studied in Phase 3 human trials. Lyophilized powder, stocked in Metro Manila. For laboratory research use only.
What it did in trials
- Higher desire scores, Phase 3
- Higher sexual desire scores over 24 weeks in RECONNECT (studies 301 and 302), Phase 3 trials in premenopausal women with hypoactive sexual desire disorder1
Choose a pack
Pack price replaces the 10% off. One compound per pack.
Pack price replaces the standing 10% off; they don't stack. One compound per pack.
Check out once for the whole cart. Pay by QR, confirm on WhatsApp.
Add more compounds if you like, then check out once. You pay by QR on your order page and send the screenshot on WhatsApp.
In the Philippines
GCash · Maya · QR Ph bank transfer · InstaPay
From abroad
- International transfer
Wise · International bank transfer · Zelle · Crypto
Payment details are sent in the WhatsApp chat once your order is confirmed.
Order by 12 noon on a weekday for same-day Metro Manila
Includes water, syringes, pads · plain box
60-day money-back guaranteeTerms
Order by 12 noon on a weekday for same-day delivery in Metro Manila
Metro Manila rider ₱150 · Luzon 1-2 days · Visayas 2-3 days · Mindanao 3-5 days
Everything to reconstitute is included
5 x 3ml water · 50 syringes · 50 pads · plain outer packaging
60-day money-back guarantee
If an accredited independent laboratory reports that this vial is not the compound on the label, we refund what you paid for it. Evidence within 60 calendar days of delivery; you do not send anything back. Terms
Updated 12 October 2026
- Human evidence
- Phase 3
- Manufacturing
- cGMP · ISO 9001 · ISO 13485
- Latest batch report
- Report pending
- Storage
- 2 to 8 °C sealed
PT-141 in the Philippines
PT-141, also written as bremelanotide, is a cyclic seven-residue melanocortin receptor agonist derived from the alpha-MSH analog melanotan II. Removing the amide group changed the pigmentation profile of the parent compound and shifted research attention to melanocortin receptor signalling instead.
The published work is distinguished from earlier compounds in the same research area by acting on central melanocortin pathways rather than on vascular smooth muscle. MC4R is the receptor subtype most of the literature concentrates on.
PT-141 is sold here as a 10mg lyophilised vial. Store it cold and in its box, away from light, both before and after mixing. The WhatsApp button on this page starts the order with the product already named; we reply with stock and the peso total, then book the delivery. Orders confirmed before 12 noon get same-day Metro Manila delivery. More on the melanocortin research is in the PT-141 guide.
Regulatory status
Bremelanotide. FDA Philippines: not established. US FDA: Approved for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. Checked 23 September 2026.
Sold for laboratory research only, not for human consumption. Primara Labs does not give medical advice or dosing guidance. Regulatory Status Tracker
Laboratory handling
Reconstitution reference
| BAC water added | Resulting concentration | Note |
|---|---|---|
| 1.0 ml | 10 mg/ml | Highest concentration, smallest volumes |
| 2.0 ml | 5 mg/ml | Common reference dilution |
Reconstitute with bacteriostatic water. Reference values are for laboratory preparation only. Other volumes: reconstitution calculator, prefilled for PT-141 10mg.
Handling and storage
Sealed vials
Store sealed lyophilised vials refrigerated at 2 to 8 °C, away from light.
Primara Labs storage instructionAdding diluent
Add the diluent slowly down the inside wall of the vial rather than straight onto the powder.
Mixing
The US prescribing instructions for tesamorelin, a lyophilised peptide medicine, tell users to swirl the vial to mix the powder and liquid, and not to shake it.
Tesamorelin US instructions for use, DailyMed · checked 23 September 2026Appearance
The same instructions say not to use the solution if it is cloudy, discoloured or has particles in it.
Tesamorelin US instructions for use, DailyMed · checked 23 September 2026After the stopper is punctured
CDC guidance, citing USP chapter 797, is that a multi-dose vial once opened is dated and discarded within 28 days unless the manufacturer states another date, and never used past its original expiry.
CDC, Preventing Unsafe Injection Practices · checked 23 September 2026What it did in trials
- Higher sexual desire scores over 24 weeks in RECONNECT (studies 301 and 302), Phase 3 trials in premenopausal women with hypoactive sexual desire disorder1
Sources for the trial highlights
- 1.RECONNECT (studies 301 and 302), 2019. Premenopausal women with hypoactive sexual desire disorder.
Benefits studied
Sexual desire in premenopausal women
Phase 3 humanIn RECONNECT (studies 301 and 302), two 24-week phase 3 trials in 1,267 premenopausal women with hypoactive sexual desire disorder, the FSFI desire score improved by 0.30 and 0.42 points more than placebo.
Kingsberg SA et al. Obstet Gynecol 2019 (RECONNECT) · checked 23 September 2026Distress about low desire
Phase 3 humanIn the same two phase 3 trials, distress related to low sexual desire (FSDS-DAO item 13) fell 0.37 and 0.29 points more than placebo.
Kingsberg SA et al. Obstet Gynecol 2019 (RECONNECT) · checked 23 September 2026Satisfying sexual events
Phase 2 humanIn a 12-week phase 2b dose-finding trial in premenopausal women with female sexual dysfunction (efficacy population 327), satisfying sexual events rose by 0.7 a month on the pooled higher-dose arms against 0.2 on placebo.
Womens Health (Lond) 2016 · checked 23 September 2026Short-term body weight
Small human studiesIn a 16-day phase 1 placebo-controlled trial in women with obesity, body weight fell 1.3 kg more on bremelanotide than on placebo.
Diabetes Obes Metab 2022 · checked 23 September 2026
Side effects reported
The most frequently reported adverse events were nausea in 40.0% on 1.75 mg, integrated phase 3 against 1.3% on placebo, flushing in 20.3% on 1.75 mg, integrated phase 3 against 1.3% on placebo, headache in 11.3% on 1.75 mg, integrated phase 3 against 1.9% on placebo and injection site reactions in 5.4% on 1.75 mg, integrated phase 3 against 0.5% on placebo (Safety profile across the clinical programme, J Womens Health 2022 (integrated double-blind phase 3, N=1,247)). The safety review reports nausea as the most common reason for stopping bremelanotide, without a rate.
Safety profile across the clinical programme, J Womens Health 2022 (integrated double-blind phase 3, N=1,247) · checked 23 September 2026Across the development programme, focal skin darkening was rare at labelled use but occurred in more than a third of people given up to 16 consecutive daily doses, and small, transient blood pressure rises were seen on ambulatory monitoring.
J Womens Health 2022 · checked 23 September 2026Findings are described as the research reported them, with the level of evidence for each. They are not a claim about any vial sold here, which is supplied for laboratory research use only.
How it works
Bremelanotide is a synthetic peptide analogue of alpha-melanocyte-stimulating hormone that acts as an agonist at melanocortin receptors, chiefly MC3R and MC4R. Investigators link MC4R agonism to its effects on sexual desire; MC4R also regulates appetite, which is why it was studied for food intake.
Targets: Melanocortin receptors, chiefly MC3R and MC4R
What the research shows
Bremelanotide (sold as PT-141) is a melanocortin receptor agonist with two completed phase 3 trials, RECONNECT 301 and 302, in 1,267 premenopausal women with hypoactive sexual desire disorder, published in 2019. The evidence pass identified nine completed human randomised controlled trials. A trial in men with erectile dysfunction carries a published expression of concern and is not counted.
Phase 3 · 24 weeks
RECONNECT (studies 301 and 302)In RECONNECT (studies 301 and 302), a phase 3 trial of bremelanotide in premenopausal women with hypoactive sexual desire disorder (n=1,267), the FSFI desire domain score difference from placebo was +0.30 points on study 301, 1.75 mg and +0.42 points on study 302, 1.75 mg over 24 weeks (Kingsberg SA et al. Obstet Gynecol 2019 (RECONNECT)).
The most frequently reported adverse events were nausea in 40.0% on 1.75 mg, integrated phase 3 against 1.3% on placebo, flushing in 20.3% on 1.75 mg, integrated phase 3 against 1.3% on placebo, headache in 11.3% on 1.75 mg, integrated phase 3 against 1.9% on placebo and injection site reactions in 5.4% on 1.75 mg, integrated phase 3 against 0.5% on placebo (Safety profile across the clinical programme, J Womens Health 2022 (integrated double-blind phase 3, N=1,247)). The safety review reports nausea as the most common reason for stopping bremelanotide, without a rate.
The first published batch report is retatrutide 20mg batch RETA-4728-A, Janoshik-tested for bacterial endotoxin (key H2KI86I8GWB4), at primaralabs.com/coa. Reports for further compounds are published there per batch as they are issued.
- Type
- Melanocortin receptor agonist (cyclic heptapeptide)
- Molecular formula
- C50H68N14O10
- Molecular weight
- 1,025.2 g/mol
- CAS
- 189691-06-3
- PubChem
- CID 9941379
- Sequence
- Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH
- Presentation
- Lyophilized powder, 10 mg / vial
- Vial size
- 10mg
- Catalogue code
- PRM-014
Frequently asked
PT-141 questions, answered
How much is PT-141 in the Philippines?
At Primara Labs, PT-141 10mg is ₱1,790 for a single vial, ₱1,393 per vial in a 5 pack (₱6,965 total) and ₱1,095 per vial in a 10 pack (₱10,950 total). Prices are in pesos and the pack price is shown on the product page before you order.
Where can I buy PT-141 in the Philippines?
Primara Labs keeps PT-141 10mg in stock in Metro Manila cold storage. Order on WhatsApp from the product page: the message is typed for you, and stock, the total and delivery are confirmed in the chat. There is no on-site checkout.
Do you deliver PT-141 to Cebu, Davao and the provinces?
Yes. Metro Manila: same day before 12 noon, Grab Express / Lalamove, ₱150; Luzon: 1 to 2 business days, J&T Express, ₱250; Visayas: 2 to 3 business days, J&T Express, ₱250; Mindanao: 3 to 5 business days, J&T Express, ₱300. Cebu is in the Visayas and Davao in Mindanao. Courier is free on orders over ₱10,000 anywhere in the Philippines. Below that, a Metro Manila rider is ₱150, J&T Express is ₱250 to Luzon and the Visayas and ₱300 to Mindanao.
Is PT-141 FDA approved in the Philippines?
Bremelanotide. FDA Philippines: not established. US FDA: Approved for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. Checked 23 September 2026. Primara Labs supplies it for research use only; it is not for human consumption.
Is PT-141 currently available?
It is in stock. Verified orders placed before noon dispatch the same day across Metro Manila, with courier delivery reaching Luzon in 1 to 2 business days, the Visayas in 2 to 3 and Mindanao in 3 to 5.
How does PT-141 relate to melanotan II?
PT-141 is derived from melanotan II by removal of the amide group. That change altered the pigmentation profile of the parent compound and moved research attention to central melanocortin receptor signalling.
What is Bremelanotide studied for?
Bremelanotide (sold as PT-141) is a melanocortin receptor agonist with two completed phase 3 trials, RECONNECT 301 and 302, in 1,267 premenopausal women with hypoactive sexual desire disorder, published in 2019. The evidence pass identified nine completed human randomised controlled trials. A trial in men with erectile dysfunction carries a published expression of concern and is not counted.
What side effects were reported for PT-141?
The most frequently reported adverse events were nausea in 40.0% on 1.75 mg, integrated phase 3 against 1.3% on placebo, flushing in 20.3% on 1.75 mg, integrated phase 3 against 1.3% on placebo, headache in 11.3% on 1.75 mg, integrated phase 3 against 1.9% on placebo and injection site reactions in 5.4% on 1.75 mg, integrated phase 3 against 0.5% on placebo (Safety profile across the clinical programme, J Womens Health 2022 (integrated double-blind phase 3, N=1,247)). The safety review reports nausea as the most common reason for stopping bremelanotide, without a rate. Across the development programme, focal skin darkening was rare at labelled use but occurred in more than a third of people given up to 16 consecutive daily doses, and small, transient blood pressure rises were seen on ambulatory monitoring.
How should PT-141 be stored?
Store sealed lyophilised vials refrigerated at 2 to 8 °C, away from light. CDC guidance, citing USP chapter 797, is that a multi-dose vial once opened is dated and discarded within 28 days unless the manufacturer states another date, and never used past its original expiry.
Does Primara Labs publish lab reports for PT-141?
The first published batch report is retatrutide 20mg batch RETA-4728-A, Janoshik-tested for bacterial endotoxin (key H2KI86I8GWB4), at primaralabs.com/coa. Reports for further compounds are published there per batch as they are issued.
All compounds supplied by Primara Labs are for laboratory research use only and are not for human consumption, diagnostic or therapeutic use. Statements on this page describe published research and have not been evaluated by the Philippine FDA. See Research Use Only terms.